Purification and Antioxidant and Anti-Inflammatory Activity of Extracellular Polysaccharopeptide from the Submerged Fermentation of Sanghuang Mushroom, Sanghuangporus lonicericola
Background: Sanghuang medicinal mushroom fungus is widely used in East Asia. In this study, antioxidant activity and anti-inflammatory properties of the new extracellular polysaccharopeptide (SePSP) was investigated. SePSP purified from the fermentation broth of the mycelium Sanghuang submerged, Sanghuangporus lonicericola stain Sanghuang CBS17 isolated from wild fruit body.
Results: SePSP extracted using ethanol precipitation procedures, followed by anion exchange and size-exclusion chromatography DEAE. The mass ratio of polysaccharides and peptides in SePSP purified component is about 4.87: 1. In determining the ability of free radicals by using DPPH, hydroxyl free radical, and superoxide anion free radicals, as well as reducing overall power, SePSP have strong antioxidant activity in a concentration-dependent vitro. Furthermore, SePSP effectively reduced dextran sulfate sodium (DSS) induced ulcerative colitis (UC) in mice.
Administration of 200 mg / kg SePSP by gavage for 7 days to prevent loss of weight; significantly reduced the mRNA levels of proinflammatory cytokines including, TNF-α and IL-1β; an increase in mRNA levels of anti-inflammatory cytokine IL-10 in the colon; and a decrease in malondialdehyde concentration of 6.42 to 4.82 umol / L in the blood at UC rats.
Conclusion: SePSP have strong antioxidant activity in vitro concentration-dependent and effectively reduced DSS-induced UC in mice. In vivo therapeutic efficacy in DSS-induced UC can be mediated through the modulation of the expression of inflammatory cytokines and inhibit oxidative stress. The findings provide a scientific rationale for utilizing the bioactive nutraceuticals from Sanghuang fungus to develop functional foods for the prevention and treatment of UC. This article is protected by copyright. All copyrights
Purification and Antioxidant and Anti-Inflammatory Activity of Extracellular Polysaccharopeptide from the Submerged Fermentation of Sanghuang Mushroom, Sanghuangporus lonicericola
The clinical utility of Highly Sensitive Lateral Flow Immunoassay determined by Titer Analysis for the Detection of anti-SARS-CoV-2 antibodies in the Point-of-Care
Coronavirus disease in 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), becoming a pandemic in early 2020. The lateral flow immunoassay for antibody testing has been seen as a cheap and fast method for determining deployable previous infection with SARS-CoV-2; However, these tests have shown low sensitivity can not be accepted.
We report a lateral flow immunoassay nine currently available and compare the sensitivity of their titers in serum to best practices enzyme-linked immunosorbent assay (ELISA) and virus neutralization assay. PCR positive for a small group, we found two devices with lateral flow immunoassay sensitivity is approximately equal titers by ELISA; This device is positive for all PCR-positive patients keep SARS-CoV-2 neutralizing antibodies. One of these devices are placed in northern Italy to test the sensitivity and specificity of the real-world clinical settings. Using the device with a fingerstick blood in a cohort of 27 patients hospitalized PCR-positive and seven controls were hospitalized, ROC curve analysis gives AUC value of 0.7646 for IgG.
Description: A sandwich quantitative ELISA assay kit for detection of Bovine Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates or other biological fluids.
Description: A sandwich quantitative ELISA assay kit for detection of Canine Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Description: A sandwich quantitative ELISA assay kit for detection of Canine Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Description: A sandwich quantitative ELISA assay kit for detection of Human Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Description: A sandwich quantitative ELISA assay kit for detection of Human Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Description: A sandwich quantitative ELISA assay kit for detection of Porcine Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates or other biological fluids.
Description: A sandwich quantitative ELISA assay kit for detection of Porcine Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates or other biological fluids.
Description: A sandwich quantitative ELISA assay kit for detection of Rat Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Description: A sandwich quantitative ELISA assay kit for detection of Rat Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Description: The protein encoded by this gene is a pleiotropic cytokine with roles in several different systems. It is involved in the induction of hematopoietic differentiation in normal and myeloid leukemia cells, induction of neuronal cell differentiation, regulator of mesenchymal to epithelial conversion during kidney development, and may also have a role in immune tolerance at the maternal-fetal interface. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene.
Description: A polyclonal antibody against LIF. Recognizes LIF from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:10000, IHC:1:25-1:100
Description: A polyclonal antibody against LIF. Recognizes LIF from Human. This antibody is Unconjugated. Tested in the following application: WB, ELISA;WB:1/500-1/2000.ELISA:1/20000
Description: LIF Antibody: LIF is a pleiotropic cytokine with roles in several different systems. It is involved in the induction of hematopoietic differentiation in normal and myeloid leukemia cells, induction of neuronal cell differentiation, regulator of mesenchymal to epithelial conversion during kidney development, and may also have a role in immune tolerance at the maternal-fetal interface. LIF was initially recognized by its ability to induce terminal differentiation of myeloid leukemic cells. It is a member of the IL-6 cytokine superfamily and can be highly glycosylated. LIF signaling is transduced through the LIF-R/gp130 receptor complex, leading to the phosphorylation and activation of the JAK/STAT pathway. Recent evidence shows that LIF inhibits cardiomyogenesis in embryonic stem cells via STAT3 activation.
Description: LIF Antibody: LIF is a pleiotropic cytokine with roles in several different systems. It is involved in the induction of hematopoietic differentiation in normal and myeloid leukemia cells, induction of neuronal cell differentiation, regulator of mesenchymal to epithelial conversion during kidney development, and may also have a role in immune tolerance at the maternal-fetal interface. LIF was initially recognized by its ability to induce terminal differentiation of myeloid leukemic cells. It is a member of the IL-6 cytokine superfamily and can be highly glycosylated. LIF signaling is transduced through the LIF-R/gp130 receptor complex, leading to the phosphorylation and activation of the JAK/STAT pathway. Recent evidence shows that LIF inhibits cardiomyogenesis in embryonic stem cells via STAT3 activation.
Description: Enzyme-linked immunosorbent assay kit for quantification of Mouse LIF in samples from serum, plasma, tissue homogenates and other biological fluids.
Description: Description of target: Leukemia inhibitory factor, or LIF, is an interleukin 6 class cytokine that affects cell growth by inhibiting differentiation. When LIF levels drop, the cells differentiate. The LIF was mapped gene to 22q11-q12.2 by Southern analysis of a series of mouse/human somatic cell hybrids and by in situ hybridization to the chromosomes of 2 normal males and some individuals with chromosomal rearrangements. The gene maps between the Philadelphia translocation BCR1 and the breakpoint of the translocation in cell line GM2324 at 22q12.2. LIF derives its name from its ability to induce the terminal differentiation of myeloid leukemic cells, thus preventing their continued growth. Other properties attributed to the cytokine include: the growth promotion and cell differentiation of different types of target cells, influence on bone metabolism, cachexia, neural development, embryogenesis and inflammation.;Species reactivity: Mouse;Application: ELISA;Assay info: ;Sensitivity: <10pg/ml
Description: Description of target: LIF has the capacity to induce terminal differentiation in leukemic cells. Its activities include the induction of hematopoietic differentiation in normal and myeloid leukemia cells, the induction of neuronal cell differentiation, and the stimulation of acute-phase protein synthesis in hepatocytes.;Species reactivity: Mouse;Application: ;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.039 ng/mL
Description: A polyclonal antibody for detection of LIF from Human. This LIF antibody is for WB, IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human LIF
Description: A polyclonal antibody for detection of LIF from Human. This LIF antibody is for WB, IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human LIF
Description: A polyclonal antibody for detection of LIF from Human. This LIF antibody is for WB, IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human LIF
Description: Leukemia Inhibitory Factor (LIF) is a lymphoid factor that promotes long-term maintenance of embryonic stem cells by suppressing spontaneous differentiation. LIF has a number of other activities including cholinergic neuron differentiation, control of stem cell pluripotency, bone and fat metabolism, mitogenesis of certain factor dependent cell lines and promotion of megakaryocyte production in vivo. Human and murine mature LIF exhibit a 78% sequence identity at the amino acid level. Human LIF is equally active on human and mouse cells. Murine LIF is approximately 1000 fold less active on human cells than human LIF.
Description: Mouse Leukemia inhibitory factor（lif）is a secreted protein which belongs to the LIF/OSM family.LIF has been implicated in a many physiological processes including development, hematopoiesis, bone metabolism, and inflammation. it has the capacity to induce terminal differentiation in leukemic cells. Its activities include the induction of hematopoietic differentiation in normal and myeloid leukemia cells, the induction of neuronal cell differentiation, and the stimulation of acute-phase protein synthesis in hepatocytes.
Description: LIF is a pleiotrophic factor produced by multiple cell types, including T cells, myelomonocytic lineages, fibroblasts, liver, heart and melanoma. LIF promotes long-term maintenance of embryonic stem cells by suppressing spontaneous differentiation. Other activities include the stimulation of acute phase protein synthesis by hepatocytes, stimulation of differentiation of cholinergic nerves, and suppression of adipogenesis by inhibiting the lipoprotein lipase in adipocytes. While human LIF is active on mouse cells and is widely used in the maintenance of murine ESC to prevent spontaneous differentiation, mouse LIF is not active on human cells due to its inability to bind to the human LIF receptor. Recombinant Murine LIF is a 19.9 kDa protein containing 180 amino acids residues, including three disulfide bonds.
Description: LIF is a pleiotrophic factor produced by multiple cell types, including T cells, myelomonocytic lineages, fibroblasts, liver, heart and melanoma. LIF promotes long-term maintenance of embryonic stem cells by suppressing spontaneous differentiation. Other activities include the stimulation of acute phase protein synthesis by hepatocytes, stimulation of differentiation of cholinergic nerves, and suppression of adipogenesis by inhibiting the lipoprotein lipase in adipocytes. While human LIF is active on mouse cells and is widely used in the maintenance of murine ESC to prevent spontaneous differentiation, mouse LIF is not active on human cells due to its inability to bind to the human LIF receptor. Recombinant Human LIF is a 19.7 kDa protein containing 180 amino acid residues, including three disulfide bonds.
Description: Leukemia inhibitory factor, or LIF, an interleukin 6 class cytokine, is a protein in cells that affects cell growth and development.Leukemia Inhibitory Factor has several functions such as cholinergic neuron differentiation, control of stem cell pluripotency, bone & fat metabolism, mitogenesis of factor dependent cell lines & promotion of megakaryocyte production in vivo. Removal of LIF pushes stem cells toward differentiation, but they retain their proliferative potential or pluripotency. Therefore LIF is used in mouse embryonic stem cell culture. It is necessary to maintain the stem cells in an undifferentiated state, however genetic manipulation of embryonic stem cells allows for LIF independent growth, notably overexpression of the gene Nanog. LIF is not required for culture of human embryonic stem cells.
Description: LIF has the capacity to induce terminal differentiation in leukemic cells. Its activities also include the induction of hematopoietic differentiation in normal and myeloid leukemia cells, the induction of neuronal cell differentiation and the stimulation of acute-phase protein synthesis in hepatocytes. LIF activates JAK & STAT signaling in human embryonic stem (ES) cells, but this pathway does not maintain pluripotency in these cells, which instead rely on FGF2-mediated ERK signaling. By contrast, mouse ES cells can be maintained by LIF-mediated JAK & STAT signaling. LIF binds to a high affinity heterodimeric receptor complex consisting of two proteins: LIF-R alpha that binds LIF with low affinity and the 130kDa (gp130) subunit that by itself does not bind LIF, but is required for high affinity binding of LIF.
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human LIF . This antibody is tested and proven to work in the following applications:
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human LIF . This antibody is tested and proven to work in the following applications:
Description: Quantitativesandwich ELISA kit for measuring Mouse Leukemia inhibitory factor, LIF in samples from serum, plasma, tissue homogenates. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.
Description: Quantitativesandwich ELISA kit for measuring Mouse Leukemia inhibitory factor, LIF in samples from serum, plasma, tissue homogenates. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.
As a comparison, this test was also tested with saliva from the same patient population and showed a decrease in discrimination between cases and controls with AUC values of 0.6841 for IgG. In addition, during a virus neutralization test, the patients were found to harbor autoantibodies to ACE2, with implications for how the immune response is profiled. We show here through the study proof-of-concept that a lateral flow device can be as analytical as sensitive as ELISA and adopted into hospital protocol; However, additional improvements to these devices is still required before their clinical deployment.
